Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Lymphoid Malignancies in Shwachman-Diamond Syndrome: Incidence, Clinical Features, and Outcomes from the North American SDS Registry

Helen D Reed, Hyunwoo Do, Edie Weller, Jason E Farrar, Christopher Gamper, Bonnie W Lau, Lauren Pommert, Ian Atkinson, Margret Joos, Sara Loveless, Sarah Steltz, Kasiani Myers, Akiko Shimamura

Blood (2023) 142 (Supplement 1): 5662.

https://doi.org/10.1182/blood-2023-174256

Published: 2023

Journal Articles

Prognostic role of circulating exosomal miRNAs in multiple myeloma

Blood (2017) 129 (17): 2429–2436.

https://doi.org/10.1182/blood-2016-09-742296

Published: 2017

Includes: Supplemental data

Journal Articles

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

Blood (2014) 123 (10): 1461–1469.

https://doi.org/10.1182/blood-2013-07-517276

Published: 2014

Journal Articles

Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia

Irene M. Ghobrial, Federico Campigotto, Timothy J. Murphy, Erica N. Boswell, Ranjit Banwait, Feda Azab, Stacey Chuma, Janet Kunsman, Amanda Donovan, Farzana Masood, Diane Warren, Scott Rodig, Kenneth C. Anderson, Paul G. Richardson, Edie Weller, Jeffrey Matous

Blood (2013) 121 (8): 1296–1303.

https://doi.org/10.1182/blood-2012-06-439307

Published: 2013

Journal Articles

Final Results of the Phase II Trial of Single Agent Panobinostat (LBH589) in Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia

Irene M. Ghobrial, MD, Ranjit Banwait, MA, Tiffany Poon, BS, Federico Campigotto, MS, Erica N Boswell, BS, Stacey Chuma, BSN, Janet Kunsman, NP, Amanda Donovan, BS, Meghan Bagshaw, Diane Warren, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Edie Weller, PhD, Timothy J. Murphy, MD, FACP, Jeffrey Matous, MD

Blood (2011) 118 (21): 2706.

https://doi.org/10.1182/blood.V118.21.2706.2706

Published: 2011

Journal Articles

The Role of Bortezomib-Containing Regimens in Improving Response in Patients with Waldenstrom Macroglobulinemia

Ranjit Banwait, MA, Edie Weller, PhD, Nitin Ropur, MD, Claudia E. Paba-Prada, MD, Lina Benajiba, Meghan Bagshaw, Steven P Treon, MD, PhD, Irene M. Ghobrial, MD

Blood (2011) 118 (21): 2713.

https://doi.org/10.1182/blood.V118.21.2713.2713

Published: 2011

Journal Articles

RVD Induction Followed by Consolidation with ASCT in Patients with Newly Diagnosed Multiple Myeloma,

Marlise R Luskin, MD, Federico Campigotto, MS, Paul G. Richardson, MD, John Koreth, MBBS, DPhil, Irene M. Ghobrial, MD, Robert Schlossman, MD, Robert J Soiffer, MD, Nikhil C. Munshi, MD, Diane Warren, Muriel Gannon, RN, Kathleen Finn, RN, Kenneth C Anderson, MD, Edie Weller, PhD, Jacob P. Laubach, MD

Blood (2011) 118 (21): 4134.

https://doi.org/10.1182/blood.V118.21.4134.4134

Published: 2011

Journal Articles

Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium

Blood (2011) 117 (26): 7070–7078.

https://doi.org/10.1182/blood-2011-04-345256

Published: 2011

Includes: Supplemental data

Journal Articles

Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma

Jacalyn Rosenblatt, Baldev Vasir, Lynne Uhl, Simona Blotta, Claire MacNamara, Poorvi Somaiya, Zekui Wu, Robin Joyce, James D. Levine, Dilani Dombagoda, Yan Emily Yuan, Karen Francoeur, Donna Fitzgerald, Paul Richardson, Edie Weller, Kenneth Anderson, Donald Kufe, Nikhil Munshi, David Avigan

Blood (2011) 117 (2): 393–402.

https://doi.org/10.1182/blood-2010-04-277137

Published: 2011

Journal Articles

The Role of Serum Immunoglobulin Free Light Chain In Response and Progression In Waldenstrom Macroglobulinemia

Xavier Leleu, MD, PhD, Wanling Xie, MS, Meghan Rourke, Ranjit Banwait, Renee Leduc, Nitin Roper, Edie Weller, Irene Ghobrial, MD

Blood (2010) 116 (21): 3095.

https://doi.org/10.1182/blood.V116.21.3095.3095

Published: 2010

Journal Articles

Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to Bortezomib

Blood (2010) 116 (21): 990.

https://doi.org/10.1182/blood.V116.21.990.990

Published: 2010

Journal Articles

The Role of PET Scan Imaging In Waldenstrom Macroglobulinemia

Ranjit Banwait, Federico Campigotto, Edie Weller, Brianna Harris, Dilek Yarar, Aldo M. Roccaro, MD, PhD, Meghan Rourke, Renee Leduc, Xavier Leleu, MD, PhD, Irene M. Ghobrial, MD

Blood (2010) 116 (21): 4153.

https://doi.org/10.1182/blood.V116.21.4153.4153

Published: 2010

Journal Articles

Updated Results of a Phase I Study of RAD001 In Combination with Lenalidomide In Patients with Relapsed or Refractory Multiple Myeloma with Pharmacodynamic and Pharmacokinetic Analysis

Blood (2010) 116 (21): 3051.

https://doi.org/10.1182/blood.V116.21.3051.3051

Published: 2010

Journal Articles

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

Blood (2010) 116 (5): 679–686.

https://doi.org/10.1182/blood-2010-02-268862

Published: 2010

Journal Articles

High Response Rates and Encouraging Time-to-Event Data with Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Final Results of a Phase I/II Study.

Blood (2009) 114 (22): 1218.

https://doi.org/10.1182/blood.V114.22.1218.1218

Published: 2009

Journal Articles

Molecular Sequaele of Activin A-Dependent Osteoblast Inhibition in Myeloma.

Blood (2009) 114 (22): 1789.

https://doi.org/10.1182/blood.V114.22.1789.1789

Published: 2009

Journal Articles

An Open-Label Phase I Study of the Safety and Efficacy of RAD001 in Combination with Lenalidomide in the Treatment of Patients with Relapsed and Relapsed/Refractory Multiple Myeloma.

Noopur Raje, MD., Paul Richardson, M.D., Parameswaran N Hari, MD, Anuj Mahindra, Sarah Kaster, BS, Christine Connolly, Linda Rivera, Gaurav Chetri, Sarah Dean, Paulette Jacobs, Ayman Saad, MD, Jacob Laubach, Irene M. Ghobrial, M.D., Robert L Schlossman, M.D., Ph.D., Jennifer Adams, Wendy Makrides, Edie Weller, PhD, Nikhil Munshi, M.D., Kenneth C. Anderson, MD

Blood (2009) 114 (22): 3856.

https://doi.org/10.1182/blood.V114.22.3856.3856

Published: 2009

Journal Articles

Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia.

Irene M. Ghobrial, M.D., Fangxin Hong, PhD, Swaminathan Padmanabhan, MD, Ashraf Z. Badros, MD, Meghan Rourke, Renee Leduc, Stacey Chuma, Janet Kunsman, NP, Diane Warren, Brianna Harris, Amy Sam, Kenneth C. Anderson, MD, Paul Richardson, M.D., Ph.D., Steven Treon, MD, PhD, Edie Weller, PhD, Jeffrey Matous

Blood (2009) 114 (22): 2727.

https://doi.org/10.1182/blood.V114.22.2727.2727

Published: 2009

Journal Articles

Final Results of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed and/or Refractory Waldenstrom Macroglobulinemia (WM).

Irene M. Ghobrial, M.D., Xavier Leleu, MD, PhD, Nancy Rubin, MD, Wanling Xie, Fangxin Hong, Stacey Chuma, RN, Renee Leduc, Marybeth Nelson, PA, Kelly O’Connor, Amy Sam, Brianna Harris, Diane Warren, Peter Sportelli, Steven P. Treon, MD, PhD, Edie Weller, PhD, Kenneth C. Anderson, MD, Paul G. Richardson, MD

Blood (2008) 112 (11): 1010.

https://doi.org/10.1182/blood.V112.11.1010.1010

Published: 2008

Journal Articles

Restoration of Bone Balance Via Activin a Inhibition Results in Anti-Myeloma Activity

Blood (2008) 112 (11): 645.

https://doi.org/10.1182/blood.V112.11.645.645

Published: 2008

NARROW

Lymphoid Malignancies in Shwachman-Diamond Syndrome: Incidence, Clinical Features, and Outcomes from the North American SDS Registry

Prognostic role of circulating exosomal miRNAs in multiple myeloma

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia

Final Results of the Phase II Trial of Single Agent Panobinostat (LBH589) in Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia

The Role of Bortezomib-Containing Regimens in Improving Response in Patients with Waldenstrom Macroglobulinemia

RVD Induction Followed by Consolidation with ASCT in Patients with Newly Diagnosed Multiple Myeloma,

Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium

Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma

The Role of Serum Immunoglobulin Free Light Chain In Response and Progression In Waldenstrom Macroglobulinemia

Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to Bortezomib

The Role of PET Scan Imaging In Waldenstrom Macroglobulinemia

Updated Results of a Phase I Study of RAD001 In Combination with Lenalidomide In Patients with Relapsed or Refractory Multiple Myeloma with Pharmacodynamic and Pharmacokinetic Analysis

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

High Response Rates and Encouraging Time-to-Event Data with Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Final Results of a Phase I/II Study.

Molecular Sequaele of Activin A-Dependent Osteoblast Inhibition in Myeloma.

An Open-Label Phase I Study of the Safety and Efficacy of RAD001 in Combination with Lenalidomide in the Treatment of Patients with Relapsed and Relapsed/Refractory Multiple Myeloma.

Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia.

Final Results of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed and/or Refractory Waldenstrom Macroglobulinemia (WM).

Restoration of Bone Balance Via Activin a Inhibition Results in Anti-Myeloma Activity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only